(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

It's the moment of truth for AbbVie. The first Humira biosimilar is set to launch later this month, with many more to follow throughout the year. AbbVie maintains that it is well prepared. After a ...

AbbVie (ABBV) has built a solid reputation among passive income-focused investors, backed by an impressive 54-year streak of ...

By Kamal Choudhury and Christy Santhosh April 29 (Reuters) - AbbVie on Wednesday reported better-than-expected quarterly revenue and profit, fueled by demand for newer immunology drugs Skyrizi and ...

This year, CVS Health plans to employ the classic "out with the old, in with the new" mantra when it comes to AbbVie’s Humira. Come April 1, the branded drug will be replaced by cheaper biosimilars ...

Evernorth's Accredo arm will make a Humira biosimilar available to patients with no out-of-pocket costs, the company announced Thursday. Accredo is the specialty pharmacy segment within Evernorth ...

Humira is an injectable prescription medication that is used to treat various inflammatory conditions. Dosages vary based on your specific condition, your weight, and other individual factors. It is ...

Another major pharmacy benefit manager is adding Humira biosimilars to its formulary beginning next year. Express Scripts, which is part of Cigna's Evernorth subsidiary, said Monday that it will add ...

Humira is a type of immunosuppressant known as a tumor necrosis factor (TNF) inhibitor. It’s prescribed to treat autoimmune conditions. TNF is a protein that plays a key role in inflammation. In ...

(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...